Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.



NERATINIB + CAPECITABINA SE DEMOSTROU SUPERIOR A COMBINAÇÃO DE LAPATINIB + CAPECITABINA , EM PACIENTES HER 2+ 3 , COM MAIS DE LINHAS DE TRATAMENTO PRÉVIOS COM (PERTUZ, TRAST, TDM1,OU MESMO NAS COMBINAÇÕES ANTI HER2 . APESAR DA DIARREIA NÃO TER SIDO FATOR LIMITANTE MAS EM MAIOR EXPRESSÃO NO SUBGRUPO ( NERA-CAP) , TEVE MAIOR PENETRAÇÃO NO SNC COM ATRASO NAS INTERVENÇÕES DE SNC COM RADIOT OU CIRURGIA
















Comentários

Postar um comentário

Postagens mais visitadas deste blog

Imagem
 https://sabcs.onlineeventpro.freeman.com/posters/25581279/Efficacy-and-tolerability-of-neoadjuvant-Pertuzumab-Trastuzumab-and-weekly-Paclitaxel-in-Locally-advanced-Her-2-positive-Breast-cancer https://sabcs.onlineeventpro.freeman.com/posters/25582333/Phase-II-pilot-study-of-trastuzumab-biosimilar-herzuma-plus-gedatolisib-in-patients-with-HER-2-positive-metastatic-breast-cancer-who-progressed-after-2-or-more-HER-2-directed https://sabcs.onlineeventpro.freeman.com/posters/25581672/HER2CLIMB-02-A-randomized-double-blind-phase-3-study-of-tucatinib-or-placebo-with-T-DM1-for-unresectable-locally-advanced-or-metastatic-HER2-breast-cancer          
Leia mais